Last reviewed · How we verify
NCT03336177: CODEGY65
Understanding Low Gynecological Cancer Delay and Help-seeking Behavior in Older Patients.
trial testing Semi-structured face to face interviews. in Gynecologic Cancer in 12 participants. Completed in 27 July 2018.
12 March 2018
Quick facts
| Lead sponsor | Institut de Cancérologie de Lorraine |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 12 |
| Start date | 30 October 2017 |
| Primary completion | 12 March 2018 |
| Estimated completion | 27 July 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- Semi-structured face to face interviews.
Conditions studied
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
- Symptoms and Signs — all drugs for Symptoms and Signs →
- Aged — all drugs for Aged →
Sponsor
Institut de Cancérologie de Lorraine — full company profile →
Who can join
65 and older, female only, with Gynecologic Cancer or Symptoms and Signs. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Systematic screening for cervical cancer stops in France at 65 years old. The incidence of certain types of gynecological neoplasia increases with age (endometrium, vulva). Diagnosis delay of 8 months has been described for uterine cancer and longer delays for vulvar cancer. The aim of our study is to understand help-seeking behavior and its delay for this type of cancer among patients older than 65.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03336177
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gynecologic Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
- NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
- NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting
Other Institut de Cancérologie de Lorraine trials
Trials by the same sponsor.
- NCT07326800 — Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cance · NA · recruiting
- NCT07089485 — Impact of Anesthesia Alarm Volume on Mental Workload in Surgical Trainees · NA · not yet recruiting
- NCT07165756 — "Mon Parcours de Vie" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot S · recruiting
- NCT06884332 — Spinal Palliation in Irradiation for Neoplastic Analgesia and Life Quality · NA · recruiting
- NCT06903104 — Acceptability and Feasibility of a Stress Prevention Program Based on Meditation and Acceptance and Commitment Therapy f · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03336177 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institut de Cancérologie de Lorraine
- Last refreshed: 8 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03336177.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing